i agree and wouldn't make much of it. either they are at the top of the dose response, or they got 1-2 more nulls in the 600mg cohort. regardless efficacy is clearly where it needs to be
i think this is posturing and wouldn't give this much weight. first of all telaprevir had comparable VL drop at 5 days, but you've got to look real hard - eyeball the graph in figure 2 at the 5 day mark from the following reference and you'll note about a 4 log drop
also the ns5a inhibitor from BMY likely has at least that much efficacy. i say this because even though the data may not be out there at 5 days, the drug had a 3 log drop after ONE dose - so i can't imagine it won't have >4 logs at 5 days..
don't get me wrong, 1625 is clearly a potent drug - but lets call a spade a spade - day 5 data is not a standard metric and some of the competing agents jsut ahven't disclosed data at day 5 specifically
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.